1 | galenical development of pharmaceuticals | | | | | | | 5 | 1.03% |
2 | hameln rds company history | | | | | | | 4 | 0.83% |
3 | our services analytical and | | | | | | | 4 | 0.83% |
4 | access en verejne prístupná | | | | | | | 4 | 0.83% |
5 | informačná služba vpois sk | | | | | | | 4 | 0.83% |
6 | affairs our products public | | | | | | | 4 | 0.83% |
7 | regulatory affairs our products | | | | | | | 4 | 0.83% |
8 | informační služba vpois cz | | | | | | | 4 | 0.83% |
9 | gmp production of apis | | | | | | | 4 | 0.83% |
10 | batch release development and | | | | | | | 4 | 0.83% |
11 | stabilities batch release development | | | | | | | 4 | 0.83% |
12 | hlásenie nežiadúcich účinkov liekov | | | | | | | 4 | 0.83% |
13 | qc and laboratory services | | | | | | | 4 | 0.83% |
14 | en verejne prístupná odborná | | | | | | | 4 | 0.83% |
15 | eu privacy statement eu | | | | | | | 4 | 0.83% |
16 | technical storage or access | | | | | | | 4 | 0.83% |
17 | rds company history our | | | | | | | 4 | 0.83% |
18 | policy eu privacy statement | | | | | | | 4 | 0.83% |
19 | the technical storage or | | | | | | | 4 | 0.83% |
20 | cookie policy eu privacy | | | | | | | 4 | 0.83% |
21 | facility certificates authority audits | | | | | | | 4 | 0.83% |
22 | analytical and galenical development | | | | | | | 3 | 0.62% |
23 | and galenical development of | | | | | | | 3 | 0.62% |
24 | of apis regulatory affairs | | | | | | | 3 | 0.62% |
25 | storage or access is | | | | | | | 2 | 0.41% |
26 | odborná informační služba vpois | | | | | | | 2 | 0.41% |
27 | služba vpois sk veřejně | | | | | | | 2 | 0.41% |
28 | přístupná odborná informační služba | | | | | | | 2 | 0.41% |
29 | sk veřejně přístupná odborná | | | | | | | 2 | 0.41% |
30 | vpois sk veřejně přístupná | | | | | | | 2 | 0.41% |
31 | služba vpois cz hlásenie | | | | | | | 2 | 0.41% |
32 | odborná informačná služba vpois | | | | | | | 2 | 0.41% |
33 | for the legitimate purpose | | | | | | | 2 | 0.41% |
34 | the legitimate purpose of | | | | | | | 2 | 0.41% |
35 | vpois cz hlásenie nežiadúcich | | | | | | | 2 | 0.41% |
36 | cz hlásenie nežiadúcich účinkov | | | | | | | 2 | 0.41% |
37 | english enus english sksk | | | | | | | 2 | 0.41% |
38 | requested by the subscriber | | | | | | | 2 | 0.41% |
39 | by the subscriber or | | | | | | | 2 | 0.41% |
40 | nežiadúcich účinkov liekov career | | | | | | | 2 | 0.41% |